How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Biomarkers Validation and Testing Market
- By Biomarker Type: Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Epigenetic Biomarkers, Transcriptomic Biomarkers
- By Application: Drug Discovery and Development, Diagnostic Testing, Prognostic Testing, Predictive Testing, Therapeutic Monitoring
- By Technology Platform: Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Mass Spectrometry, Microarray Analysis, Immunoassays
- By End User: Pharmaceutical and Biotechnology Companies, Clinical Research Organizations (CROs), Diagnostic Laboratories, Academic and Research Institutes, Hospitals and Clinics
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Genomic Biomarkers leads By Biomarker Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 281 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.170 →
- 11 Company Profiles 15 players: SWOT & benchmarking p.178 →
Full report · locked preview
Everything inside the Biomarkers Validation and Testing Market report
A complete, evidence-based study - 11 chapters and 118 sections covering market size, segmentation across 4 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Biomarker Type 5
Application 5
Technology Platform 5
End User 5
Companies profiled
Thermo Fisher Scientific
Roche Diagnostics
QIAGEN
Abbott Laboratories
Bio-Rad Laboratories
Agilent Technologies
PerkinElmer
Danaher Corporation
Illumina
Sartorius
Charles River Laboratories
Eurofins Scientific
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Thermo Fisher Scientific
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Roche Diagnostics
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →QIAGEN
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Abbott Laboratories
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Bio-Rad Laboratories
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Agilent Technologies
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →PerkinElmer
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Danaher Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Illumina
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Sartorius
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Charles River Laboratories
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Eurofins Scientific
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →ICON plc
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →LabCorp
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Covance
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →
Global · 2025–2033
$2,715M by 2033 · 8.8% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Genomic Biomarkers45.8
- Proteomic Biomarkers14.5
- Metabolomic Biomarkers8.0
- Epigenetic Biomarkers19.2
- Transcriptomic Biomarkers12.6
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$455.3M → $908.8M · 9.0%
Europe$317.4M → $653.4M · 9.4%
Asia Pacific$289.8M → $620.9M · 10.0%
Latin America$179.4M → $316.3M · 7.3%
Middle East and Africa$138.0M → $246.1M · 7.5%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →8.782026
8.792027
8.812028
8.812029
8.842030
8.852031
8.862032
8.872033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Thermo Fisher Scientific14.6
- Roche Diagnostics24.5
- QIAGEN11.5
- Abbott Laboratories7.0
- Bio-Rad Laboratories6.9
- Agilent Technologies7.6
- Others27.9
Segment contribution to growth (%)
Fig. 18 · p.39 →Biomarker Type22.0%
Application22.6%
Technology Platform35.5%
End User19.9%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America33.1
- Europe23.8
- Asia Pacific22.6
- Latin America11.5
- Middle East and Africa9.0
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Thermo Fisher Scientific | 74 | 78 | 89 | 78 | 79 | 78 | 79 |
| Roche Diagnostics | 91 | 81 | 69 | 85 | 89 | 91 | 84 |
| QIAGEN | 68 | 65 | 68 | 84 | 80 | 72 | 73 |
| Abbott Laboratories | 79 | 65 | 60 | 81 | 79 | 70 | 72 |
| Bio-Rad Laboratories | 56 | 70 | 65 | 71 | 67 | 70 | 67 |
| Agilent Technologies | 67 | 64 | 58 | 52 | 50 | 52 | 57 |
| PerkinElmer | 62 | 58 | 64 | 55 | 45 | 45 | 55 |
| Danaher Corporation | 46 | 48 | 53 | 42 | 51 | 48 | 48 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Thermo Fisher Scientific
- Roche Diagnostics
- QIAGEN
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific | ✓ | ◐ | ◐ | ✓ | ◐ | ◐ |
| Roche Diagnostics | ✓ | ✓ | ✓ | ◐ | ✓ | ✓ |
| QIAGEN | ◐ | ✓ | ◐ | ✓ | ◐ | ◐ |
| Abbott Laboratories | ◐ | ◐ | − | ✓ | ✓ | ✓ |
| Bio-Rad Laboratories | − | ◐ | − | ◐ | − | ◐ |
| Agilent Technologies | − | ✓ | ◐ | − | − | ◐ |
| PerkinElmer | ◐ | − | ◐ | ◐ | − | − |
| Danaher Corporation | − | ◐ | ◐ | ◐ | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Roche Diagnostics84
2Thermo Fisher Scientific79
3QIAGEN73
4Abbott Laboratories72
5Bio-Rad Laboratories67
6Agilent Technologies57
7PerkinElmer55
8Danaher Corporation48
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Thermo Fisher ScientificRoche Diagnostics
Challenger3
Strong scale, closing on the leaders.
QIAGENAbbott LaboratoriesBio-Rad Laboratories
Contender1
Focused players with pockets of strength.
Agilent Technologies
Niche2
Specialists in a single segment or region.
PerkinElmerDanaher Corporation
Go-to-market strategy
Land Biomarker Type in North America, then scale across Biomarkers Validation and Testing Market — a $750M beachhead inside a $12.6B market.
Beachhead (SOM)$750Mobtainable near-term
Serviceable (SAM)$4.37Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion87 fit
Genomic Biomarkers
Best fit — highest urgency & budget in Biomarker Type.
Economic buyer80 fit
Proteomic Biomarkers
Strong fit — clear ROI and a fast path to value.
End user66 fit
Metabolomic Biomarkers
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Biomarker Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Application & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Technology Platform
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales43%
Partner / channel28%
Digital / self-serve20%
Marketplaces9%
Positioning & messaging
§GTM 2 · p.194 →For Biomarker Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Biomarkers Validation and Testing Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified42%
Sales qualified23%
Evaluation12%
Closed-won7%
$18.4KCAC
$65KLTV
3.5:1LTV : CAC
< 4 moCAC payback
Investment thesis
Biomarkers Validation and Testing Market is a durable-growth opportunity — $2.81B by 2033, compounding at 7.9%.
TAM · 2025$1.53Btoday
TAM · 2033$2.81Bforecast
CAGR7.9%2027–2033
Cumulative$19.0Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$2.81BTotal addressable market
SAM$1.08BServiceable available market
SOM$209MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →7.9% CAGR
Demand compounds through 2033, outpacing GDP across Biomarker Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Biomarker Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$2.81BLarge & growingTAM by 2033 at 7.9% CAGR
$1.08BServiceable nowreachable with today’s model
$209MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$2.19BBear5.1% CAGR
$2.81BBase7.9% CAGR
$3.59BBull10.4% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Application optionality
- Customer concentrationBroaden installed base beyond top accounts
Board pack · executive summary
Biomarkers Validation and Testing Market — a $3.52B market by 2033. Plan: grow share from 6.2% to 12.3%.
Market size · 2033$3.52Btotal addressable
Market CAGR7.3%2027–2033
Target share12.3%from 6.2% today
Revenue ambition$433Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 6.2% | 12.3% | Behind |
| Revenue | $211M | $433M | Behind |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Ahead |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | Ahead |
| Gross margin | 36.1% | 43.3% | Ahead |
| Customer retention | 87.9% | 93.1% | Behind |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Biomarker Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Application capability
A defensible second engine — invest in Application to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Biomarker Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Application
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $57M capacity & capability investment
- Greenlight bolt-on M&A in Application
- Authorise North America expansion plan
- Fund R&D program for Biomarker Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownBehind
- Competitive share lossAt risk
- Input-cost & supply riskAt risk
- Regulatory / policy changeAt risk
- Execution & talentAt risk
Sales deck · value proposition
Win the Biomarkers Validation and Testing Market conversation — a $6.54B market you can size, segment and defend in minutes.
Market size · 2033$6.54Btotal opportunity
Growth4.7%CAGR to 2033
Addressable buyers1,034+accounts in scope
Typical ROI6.3×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Biomarker Type
Goal Grow share in Biomarker Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6.3×return on cost, year one
< 4 mopayback period
$52K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Thermo Fisher ScientificRoche DiagnosticsQIAGENAbbott LaboratoriesBio-Rad LaboratoriesAgilent TechnologiesPerkinElmerDanaher Corporation+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Biomarkers Validation and Testing Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Biomarkers Validation and Testing Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Biomass Briquette & Pellets Market
Market size, share, segmentation and regional forecast.
$3.4B market · 2025 base year
View reportBiomass Briquette Boiler Market
Market size, share, segmentation and regional forecast.
$3.2B market · 2025 base year
View reportBiomass Briquettes and Pellets Market
Market size, share, segmentation and regional forecast.
$3.3B market · 2025 base year
View reportBiomass Briquetting Feed Market
Market size, share, segmentation and regional forecast.
$2.5B market · 2025 base year
View reportBiomass Briquetting Market
Market size, share, segmentation and regional forecast.
$2.0B market · 2025 base year
View reportBiomass Curing Equipment Market
Market size, share, segmentation and regional forecast.
$3.3B market · 2025 base year
View reportBiomass Energy Technology Market
Market size, share, segmentation and regional forecast.
$3.9B market · 2025 base year
View reportBiomass Fuel Briquette Market
Market size, share, segmentation and regional forecast.
$4.6B market · 2025 base year
View reportBiomass Fuel Calorimeter Market
Market size, share, segmentation and regional forecast.
$3.3B market · 2025 base year
View reportBiomass Fuel Pellet Machine Market
Market size, share, segmentation and regional forecast.
$1.4B market · 2025 base year
View reportBiomass Granulation Equipment Market
Market size, share, segmentation and regional forecast.
$1.4B market · 2025 base year
View reportBiomass Grinder Market
Market size, share, segmentation and regional forecast.
$1.6B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report ships as a formatted PDF, a fully editable XLSX containing all underlying data tables, and a presentation-ready PPT deck - so you can re-chart, re-model, or drop any figure straight into your own deck.